Obagi Medical Products to Report Fourth Quarter and Full Year 2011 Financial Results and Host a Conference Call on March 8

LONG BEACH, Calif.--()--Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetic and therapeutic skin health systems, today announced it will report financial results for its fourth quarter and year ended December 31, 2011 after market close on Thursday, March 8, followed by an investor conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

Investors interested in participating in the live call can dial 877-407-9039 from the U.S. and international callers can dial 201-689-8470. A telephone replay will be available approximately two hours after the call concludes through Thursday, March 22, by dialing 877-870-5176 from the U.S., or 858-384-5517 for international callers, and entering replay pin #387544.

There also will be a simultaneous webcast on the Investor Relations section of the Company’s web site at www.obagi.com. For those unable to participate during the live broadcast, the webcast will be available for 30 days.

About Obagi Medical Products, Inc.

Obagi Medical Products is a specialty pharmaceutical company that develops, markets and sells, and is a leading provider of, proprietary topical aesthetic and therapeutic prescription-strength skin care systems in the physician-dispensed market. Using its Penetrating Therapeutics™ technologies, Obagi Medical’s products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin including premature aging, photodamage, hyperpigmentation (irregular or patchy discoloration of the skin), acne, sun damage, rosacea, and soft tissue deficits, such as fine lines and wrinkles. Obagi Medical’s portfolio, which includes cosmetic, over-the-counter and prescription products, including 4% hydroquinone, is sold and promoted only through physician offices and requires education by a physician on proper use. The history of Obagi’s skin care product introductions is as follows: Obagi Nu-Derm®, Obagi-C® Rx (a prescription-strength vitamin C and hydroquinone system), Obagi® Professional-C (a line of highly stable vitamin C serums), Obagi Condition &Enhance® for use with cosmetic procedures to enhance patient outcomes and satisfaction, Obagi ELASTIderm® Eye Treatment and Obagi CLENZIderm® M.D. acne therapeutic systems, a formulation of Obagi CLENZIderm M.D. Systems for normal to dry skin, and Obagi ELASTIderm Décolletage System, Obagi Rosaclear® System, Obagi ELASTILash® Eyelash Solution, Obagi Blue Peel RADIANCE™, and Nu-Derm® Sun Shield SPF 50. Visit http://www.obagi.com for information.

Blue Peel RADIANCE, ELASTILash and Penetrating Therapeutics are trademarks, and Obagi, the Obagi logo, Condition & Enhance, ELASTIderm, Nu-Derm, Obagi-C, Obagi CLENZIderm and Rosaclear are registered trademarks, of Obagi Medical Products, Inc. and/or its affiliates in the United States and certain other countries.

Contacts

Obagi Medical Products, Inc.
Preston Romm, 562-628-1007
CFO, EVP of Finance, Operations and Administration
or
Investor Relations:
McGuinness Consulting
Ina McGuinness, 805-427-1372

Sharing

Contacts

Obagi Medical Products, Inc.
Preston Romm, 562-628-1007
CFO, EVP of Finance, Operations and Administration
or
Investor Relations:
McGuinness Consulting
Ina McGuinness, 805-427-1372